Pipeline2019-10-10T11:59:20+00:00

seperator

Pipeline Status

seperator

The initial focus of Ethris is to leverage our pioneering SNIM® RNA technology platform to develop therapies for severe pulmonary diseases, especially those with high unmet need such as Primary Ciliary Dyskinesia (PCD). Beyond this, the versatility of our first-in-class biopharmaceutical platform for replacing or augmenting missing or non-functional proteins will ultimately enable us to address an array of diverse respiratory diseases.

Learn more about our technology.

GO TO TECHNOLOGY